Roche pulls dangling accelerated approval for Tecentriq in triple-negative breast cancer
Roche on Friday decided to voluntarily pull an indication won via the FDA’s accelerated approval pathway for its blockbuster PD-L1 drug Tecentriq.
This is the third accelerated approval to be pulled following an ODAC meeting last April to review six indications from Roche, Merck and Bristol Myers Squibb blockbuster cancer drugs, where confirmatory trials failed. This is also the fourth accelerated approval to be pulled in the last month.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.